Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

DEN SELVEJENDE INSTITUTION BIO-HUSET FOND Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8% 2.8%   Bankruptcy risk   4.7% 4.6% 6.9% 4.4% 7.3% 6.7% 10.3% 10.3%   Credit score (0-100)   47 46 33 47 32 36 24 24   Credit rating   BBB BBB BBB BBB BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   561 486 237 619 389 895 0.0 0.0   EBITDA   170 108 -83.2 226 90.1 655 0.0 0.0   EBIT   142 70.6 -135 183 57.6 143 0.0 0.0   Pre-tax profit (PTP)   140.2 62.5 -144.1 171.9 56.9 144.4 0.0 0.0   Net earnings   118.8 62.4 -144.1 171.9 56.9 97.2 0.0 0.0   Pre-tax profit without non-rec. items   140 62.5 -144 172 56.9 144 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   67.5 317 265 253 2,565 4,958 0.0 0.0   Shareholders equity total   1,340 1,403 1,260 1,522 1,579 1,676 1,286 1,286   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,509 1,533 1,699 2,381 4,781 5,850 1,286 1,286   Net Debt   -1,344 -1,093 -1,304 -2,025 -1,711 -795 -1,286 -1,286     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   561 486 237 619 389 895 0.0 0.0   Gross profit growth   9.1% -13.3% -51.4% 161.7% -37.2% 130.4% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,509 1,533 1,699 2,381 4,781 5,850 1,286 1,286   Balance sheet change%   10.1% 1.6% 10.8% 40.1% 100.8% 22.3% -78.0% 0.0%   Added value   170.0 108.0 -83.2 226.1 100.5 654.6 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -23 212 -104 -55 2,279 1,882 -4,958 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 -1.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   25.3% 14.5% -57.2% 29.6% 14.8% 16.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   9.9% 4.6% -8.4% 9.0% 1.6% 2.7% 0.0% 0.0%   ROI %   11.1% 5.1% -10.2% 13.2% 3.8% 8.8% 0.0% 0.0%   ROE %   9.3% 4.6% -10.8% 12.4% 3.7% 6.0% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   92.0% 96.6% 81.7% 68.4% 34.3% 29.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -790.3% -1,011.8% 1,566.3% -895.7% -1,899.3% -121.5% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   12.3 24.3 4.9 3.0 0.7 0.2 0.0 0.0   Current Ratio   8.5 9.3 3.3 2.5 0.7 0.2 0.0 0.0   Cash and cash equivalent   1,343.5 1,092.7 1,303.8 2,024.7 1,711.0 795.5 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,272.9 1,085.6 995.2 1,268.9 -985.7 -3,234.5 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   170 108 -83 226 100 655 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   170 108 -83 226 90 655 0 0   EBIT / employee   142 71 -135 183 58 143 0 0   Net earnings / employee   119 62 -144 172 57 97 0 0